{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:29:22Z","timestamp":1772166562866,"version":"3.50.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T00:00:00Z","timestamp":1591920000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T00:00:00Z","timestamp":1591920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Syst Rev"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>A model that can predict treatment response for a patient with specific baseline characteristics would help decision-making in personalized medicine. The aim of the study is to develop such a model in the treatment of rheumatoid arthritis (RA) patients who receive certolizumab (CTZ) plus methotrexate (MTX) therapy, using individual participant data meta-analysis (IPD-MA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We will search Cochrane CENTRAL, PubMed, and Scopus as well as clinical trial registries, drug regulatory agency reports, and the pharmaceutical company websites from their inception onwards to obtain randomized controlled trials (RCTs) investigating CTZ plus MTX compared with MTX alone in treating RA. We will request the individual-level data of these trials from an independent platform (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/vivli.org\">http:\/\/vivli.org<\/jats:ext-link>\n                      ). The primary outcome is efficacy defined as achieving either\n                      <jats:italic>remission<\/jats:italic>\n                      (based on ACR-EULAR Boolean or index-based remission definition) or\n                      <jats:italic>low disease activity<\/jats:italic>\n                      (based on either of the validated composite disease activity measures). The secondary outcomes include ACR50 (50% improvement based on ACR core set variables) and adverse events. We will use a two-stage approach to develop the prediction model. First, we will construct a risk model for the outcomes via logistic regression to estimate the baseline risk scores. We will include baseline demographic, clinical, and biochemical features as covariates for this model. Next, we will develop a meta-regression model for treatment effects, in which the stage 1 risk score will be used both as a prognostic factor and as an effect modifier. We will calculate the probability of having the outcome for a new patient based on the model, which will allow estimation of the absolute and relative treatment effect. We will use R for our analyses, except for the second stage which will be performed in a Bayesian setting using .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This is a study protocol for developing a model to predict treatment response for RA patients receiving CTZ plus MTX in comparison with MTX alone, using a two-stage approach based on IPD-MA. The study will use a new modeling approach, which aims at retaining the statistical power. The model may help clinicians individualize treatment for particular patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>PROSPERO registration number pending (ID#157595).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13643-020-01401-x","type":"journal-article","created":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T14:02:34Z","timestamp":1591970554000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Predicting the treatment response of certolizumab for individual adult patients with rheumatoid arthritis: protocol for an individual participant data meta-analysis"],"prefix":"10.1186","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5271-5126","authenticated-orcid":false,"given":"Yan","family":"Luo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantina","family":"Chalkou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Funada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgia","family":"Salanti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshi A.","family":"Furukawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,12]]},"reference":[{"issue":"6","key":"1401_CR1","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","volume":"76","author":"JS Smolen","year":"2017","unstructured":"Smolen JS, Landewe R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, Nam J, Ramiro S, Voshaar M, van Vollenhoven R, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960\u201377.","journal-title":"Ann Rheum Dis"},{"key":"1401_CR2","unstructured":"Committee for Medicinal Products for Human Use (CHMP): Guideline on clinical investigation of medicinal products for the treatment of rheumatoid arthritis. . In. Edited by Agency EM, vol. CPMP\/EWP\/556\/95 London; 2018."},{"issue":"18","key":"1401_CR3","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1002\/sim.5732","volume":"32","author":"TP Debray","year":"2013","unstructured":"Debray TP, Moons KG, Ahmed I, Koffijberg H, Riley RD. A framework for developing, implementing, and evaluating clinical prediction models in an individual participant data meta-analysis. Stat Med. 2013;32(18):3158\u201380.","journal-title":"Stat Med"},{"key":"1401_CR4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1471-2288-14-3","volume":"14","author":"I Ahmed","year":"2014","unstructured":"Ahmed I, Debray TP, Moons KG, Riley RD. Developing and validating risk prediction models in an individual participant data meta-analysis. BMC Med Res Methodol. 2014;14:3.","journal-title":"BMC Med Res Methodol"},{"issue":"10","key":"1401_CR5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001886","volume":"12","author":"TP Debray","year":"2015","unstructured":"Debray TP, Riley RD, Rovers MM, Reitsma JB, Moons KG. Cochrane IPDM-aMg: Individual participant data (IPD) meta-analyses of diagnostic and prognostic modeling studies: guidance on their use. PLoS Med. 2015;12(10):e1001886.","journal-title":"PLoS Med"},{"issue":"1","key":"1401_CR6","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s12874-019-0817-6","volume":"19","author":"M Belias","year":"2019","unstructured":"Belias M, Rovers MM, Reitsma JB, Debray TPA, IntHout J. Statistical approaches to identify subgroups in meta-analysis of individual participant data: a simulation study. BMC Med Res Methodol. 2019;19(1):183.","journal-title":"BMC Med Res Methodol"},{"issue":"2","key":"1401_CR7","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1136\/ard.2008.105064","volume":"69","author":"A Finckh","year":"2010","unstructured":"Finckh A, Ciurea A, Brulhart L, Moller B, Walker UA, Courvoisier D, Kyburz D, Dudler J, Gabay C. Arthritis: Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent? Ann Rheum Dis. 2010;69(2):387\u201393.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"1401_CR8","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1080\/1744666X.2018.1465409","volume":"14","author":"S Ling","year":"2018","unstructured":"Ling S, Bluett J, Barton A. Prediction of response to methotrexate in rheumatoid arthritis. Expert Rev Clin Immunol. 2018;14(5):419\u201329.","journal-title":"Expert Rev Clin Immunol"},{"issue":"7","key":"1401_CR9","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.mayocp.2017.05.009","volume":"92","author":"CA Wijbrandts","year":"2017","unstructured":"Wijbrandts CA, Tak PP. Prediction of response to targeted treatment in rheumatoid arthritis. Mayo Clin Proc. 2017;92(7):1129\u201343.","journal-title":"Mayo Clin Proc"},{"issue":"8","key":"1401_CR10","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1136\/annrheumdis-2018-214877","volume":"78","author":"A Spiliopoulou","year":"2019","unstructured":"Spiliopoulou A, Colombo M, Plant D, Nair N, Cui J, Coenen MJ, Ikari K, Yamanaka H, Saevarsdottir S, Padyukov L, et al. Association of response to TNF inhibitors in rheumatoid arthritis with quantitative trait loci for CD40 and CD39. Ann Rheum Dis. 2019;78(8):1055\u201361.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1401_CR11","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.0606","volume":"2","author":"B Norgeot","year":"2019","unstructured":"Norgeot B, Glicksberg BS, Trupin L, Lituiev D, Gianfrancesco M, Oskotsky B, Schmajuk G, Yazdany J, Butte AJ. Assessment of a deep learning model based on electronic health record data to forecast clinical outcomes in patients with rheumatoid arthritis. JAMA Netw Open. 2019;2(3):e190606.","journal-title":"JAMA Netw Open"},{"key":"1401_CR12","doi-asserted-by":"crossref","first-page":"k4245","DOI":"10.1136\/bmj.k4245","volume":"363","author":"DM Kent","year":"2018","unstructured":"Kent DM, Steyerberg E, van Klaveren D. Personalized evidence based medicine: predictive approaches to heterogeneous treatment effects. BMJ. 2018;363:k4245.","journal-title":"BMJ"},{"key":"1401_CR13","doi-asserted-by":"crossref","first-page":"c221","DOI":"10.1136\/bmj.c221","volume":"340","author":"RD Riley","year":"2010","unstructured":"Riley RD, Lambert PC, Abo-Zaid G. Meta-analysis of individual participant data: rationale, conduct, and reporting. BMJ. 2010;340:c221.","journal-title":"BMJ"},{"issue":"4","key":"1401_CR14","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/jrsm.1160","volume":"6","author":"TP Debray","year":"2015","unstructured":"Debray TP, Moons KG, van Valkenhoef G, Efthimiou O, Hummel N, Groenwold RH, Reitsma JB. GetReal Methods Review G: Get real in individual participant data (IPD) meta-analysis: a review of the methodology. Res Synth Methods. 2015;6(4):293\u2013309.","journal-title":"Res Synth Methods"},{"issue":"1","key":"1401_CR15","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1186\/s13643-017-0630-4","volume":"6","author":"B Chen","year":"2017","unstructured":"Chen B, Benedetti A. Quantifying heterogeneity in individual participant data meta-analysis with binary outcomes. Syst Rev. 2017;6(1):243.","journal-title":"Syst Rev"},{"issue":"9","key":"1401_CR16","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.jclinepi.2010.11.016","volume":"64","author":"DJ Fisher","year":"2011","unstructured":"Fisher DJ, Copas AJ, Tierney JF, Parmar MK. A critical review of methods for the assessment of patient-level interactions in individual participant data meta-analysis of randomized trials, and guidance for practitioners. J Clin Epidemiol. 2011;64(9):949\u201367.","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"1401_CR17","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1159\/000489227","volume":"87","author":"TA Furukawa","year":"2018","unstructured":"Furukawa TA, Efthimiou O, Weitz ES, Cipriani A, Keller MB, Kocsis JH, Klein DN, Michalak J, Salanti G, Cuijpers P, et al. Cognitive-behavioral analysis system of psychotherapy, drug, or their combination for persistent depressive disorder: personalizing the treatment choice using individual participant data network metaregression. Psychother Psychosom. 2018;87(3):140\u201353.","journal-title":"Psychother Psychosom"},{"key":"1401_CR18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","volume":"4","author":"D Moher","year":"2015","unstructured":"Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA, Group P-P. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1.","journal-title":"Syst Rev"},{"issue":"16","key":"1401_CR19","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1001\/jama.2015.3656","volume":"313","author":"LA Stewart","year":"2015","unstructured":"Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, Tierney JF, Group P-ID. Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement. JAMA. 2015;313(16):1657\u201365.","journal-title":"JAMA"},{"issue":"9","key":"1401_CR20","first-page":"2569","volume":"62","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, et al. Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010. 2010;62(9):2569\u201381.","journal-title":"Arthritis Rheum 2010"},{"issue":"9","key":"1401_CR21","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard.2010.138461","volume":"69","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, et al. rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010. 2010;69(9):1580\u20138.","journal-title":"Ann Rheum Dis 2010"},{"issue":"3","key":"1401_CR22","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315\u201324.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"1401_CR23","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1136\/ard.2011.149765","volume":"70","author":"DT Felson","year":"2011","unstructured":"Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, Aletaha D, Allaart CF, Bathon J, Bombardieri S, et al. American College of Rheumatology\/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis. 2011;70(3):404\u201313.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1401_CR24","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.rdc.2005.09.005","volume":"32","author":"D Aletaha","year":"2006","unstructured":"Aletaha D, Smolen JS. The definition and measurement of disease modification in inflammatory rheumatic diseases. Rheum Dis Clin North Am. 2006;32(1):9\u201344 vii.","journal-title":"Rheum Dis Clin North Am"},{"issue":"5 Suppl 39","key":"1401_CR25","first-page":"S93","volume":"23","author":"J Fransen","year":"2005","unstructured":"Fransen J, van Riel PL. The Disease Activity Score and the EULAR response criteria. Clin Exp Rheumatol. 2005;23(5 Suppl 39):S93\u20139.","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"1401_CR26","doi-asserted-by":"crossref","first-page":"R796","DOI":"10.1186\/ar1740","volume":"7","author":"D Aletaha","year":"2005","unstructured":"Aletaha D, Nell VP, Stamm T, Uffmann M, Pflugbeil S, Machold K, Smolen JS. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther. 2005;7(4):R796\u2013806.","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"1401_CR27","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1002\/art.21235","volume":"52","author":"D Aletaha","year":"2005","unstructured":"Aletaha D, Ward MM, Machold KP, Nell VP, Stamm T, Smolen JS. Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. Arthritis Rheum. 2005;52(9):2625\u201336.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"1401_CR28","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1002\/art.23733","volume":"58","author":"D Aletaha","year":"2008","unstructured":"Aletaha D, Funovits J, Smolen JS. The importance of reporting disease activity states in rheumatoid arthritis clinical trials. Arthritis Rheum. 2008;58(9):2622\u201331.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"1401_CR29","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","volume":"38","author":"DT Felson","year":"1995","unstructured":"Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, Katz LM, Lightfoot R Jr, Paulus H, Strand V, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995;38(6):727\u201335.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"1401_CR30","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1177\/1759720X16654476","volume":"8","author":"F Espinoza","year":"2016","unstructured":"Espinoza F, Fabre S, Pers YM. Remission-induction therapies for early rheumatoid arthritis: evidence to date and clinical implications. Ther Adv Musculoskelet Dis. 2016;8(4):107\u201318.","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"66","key":"1401_CR31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta22660","volume":"22","author":"R Archer","year":"2018","unstructured":"Archer R, Hock E, Hamilton J, Stevens J, Essat M, Poku E, Clowes M, Pandor A, Stevenson M. Assessing prognosis and prediction of treatment response in early rheumatoid arthritis: systematic reviews. Health Technol Assess. 2018;22(66):1\u2013294.","journal-title":"Health Technol Assess"},{"issue":"1","key":"1401_CR32","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13075-017-1266-4","volume":"19","author":"K Albrecht","year":"2017","unstructured":"Albrecht K, Zink A. Poor prognostic factors guiding treatment decisions in rheumatoid arthritis patients: a review of data from randomized clinical trials and cohort studies. Arthritis Res Ther. 2017;19(1):68.","journal-title":"Arthritis Res Ther"},{"key":"1401_CR33","doi-asserted-by":"crossref","first-page":"12460","DOI":"10.1038\/ncomms12460","volume":"7","author":"SK Sieberts","year":"2016","unstructured":"Sieberts SK, Zhu F, Garcia-Garcia J, Stahl E, Pratap A, Pandey G, Pappas D, Aguilar D, Anton B, Bonet J, et al. Crowdsourced assessment of common genetic contribution to predicting anti-TNF treatment response in rheumatoid arthritis. Nat Commun. 2016;7:12460.","journal-title":"Nat Commun"},{"key":"1401_CR34","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovic J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","journal-title":"BMJ"},{"issue":"5","key":"1401_CR35","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1002\/sim.7141","volume":"36","author":"DL Burke","year":"2017","unstructured":"Burke DL, Ensor J, Riley RD. Meta-analysis using individual participant data: one-stage and two-stage approaches, and why they may differ. Stat Med. 2017;36(5):855\u201375.","journal-title":"Stat Med"},{"key":"1401_CR36","unstructured":"Carpenter JR, Kenward MG: Missing data in randomised controlled trials: a practical guide. In. https:\/\/researchonline.lshtm.ac.uk\/id\/eprint\/4018500: Health Technology Assessment Methodology Programme, Birmingham, p.199; 2007."},{"issue":"1","key":"1401_CR37","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1161\/CIRCOUTCOMES.113.000497","volume":"7","author":"JF Burke","year":"2014","unstructured":"Burke JF, Hayward RA, Nelson JP, Kent DM. Using internally developed risk models to assess heterogeneity in treatment effects in clinical trials. Circ Cardiovasc Qual Outcomes. 2014;7(1):163\u20139.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"1","key":"1401_CR38","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.2517-6161.1996.tb02080.x","volume":"58","author":"R Tibshirani","year":"1996","unstructured":"Tibshirani R. Regression shrinkage and selection via the lasso. Journal of the Royal Statistical Society Series B (Methodological). 1996;58(1):267\u201388.","journal-title":"Journal of the Royal Statistical Society Series B (Methodological)"},{"issue":"9","key":"1401_CR39","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1136\/heartjnl-2011-301246","volume":"98","author":"KG Moons","year":"2012","unstructured":"Moons KG, Kengne AP, Woodward M, Royston P, Vergouwe Y, Altman DG, Grobbee DE. Risk prediction models: I. Development, internal validation, and assessing the incremental value of a new (bio)marker. Heart. 2012;98(9):683\u201390.","journal-title":"Heart"},{"issue":"7","key":"1401_CR40","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1002\/sim.7992","volume":"38","author":"RD Riley","year":"2019","unstructured":"Riley RD, Snell KI, Ensor J, Burke DL, Harrell FE Jr, Moons KG, Collins GS. Minimum sample size for developing a multivariable prediction model: PART II - binary and time-to-event outcomes. Stat Med. 2019;38(7):1276\u201396.","journal-title":"Stat Med"},{"key":"1401_CR41","doi-asserted-by":"crossref","unstructured":"Khan NA, Singh M, Spencer HJ, Torralba KD: Randomized controlled trials of rheumatoid arthritis registered at ClinicalTrials.gov: what gets published and when. Arthritis Rheumatol 2014, 66(10):2664-2674.","DOI":"10.1002\/art.38784"},{"issue":"8","key":"1401_CR42","doi-asserted-by":"crossref","first-page":"iii","DOI":"10.3310\/hta14080","volume":"14","author":"F Song","year":"2010","unstructured":"Song F, Parekh S, Hooper L, Loke YK, Ryder J, Sutton AJ, Hing C, Kwok CS, Pang C, Harvey I. Dissemination and publication of research findings: an updated review of related biases. Health Technol Assess. 2010;14(8):iii ix-xi, 1-193.","journal-title":"Health Technol Assess"},{"issue":"Suppl 1","key":"1401_CR43","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2015-000057","volume":"1","author":"S Monti","year":"2015","unstructured":"Monti S, Montecucco C, Bugatti S, Caporali R. Rheumatoid arthritis treatment: the earlier the better to prevent joint damage. RMD Open. 2015;1(Suppl 1):e000057.","journal-title":"RMD Open"},{"issue":"4","key":"1401_CR44","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1136\/ard.2008.092577","volume":"68","author":"M Dougados","year":"2009","unstructured":"Dougados M, Schmidely N, Le Bars M, Lafosse C, Schiff M, Smolen JS, Aletaha D, van Riel P, Wells G. Evaluation of different methods used to assess disease activity in rheumatoid arthritis: analyses of abatacept clinical trial data. Ann Rheum Dis. 2009;68(4):484\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1401_CR45","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1186\/s13063-016-1402-5","volume":"17","author":"F Ibrahim","year":"2016","unstructured":"Ibrahim F, Tom BD, Scott DL, Prevost AT. A systematic review of randomised controlled trials in rheumatoid arthritis: the reporting and handling of missing data in composite outcomes. Trials. 2016;17(1):272.","journal-title":"Trials"}],"container-title":["Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-020-01401-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13643-020-01401-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-020-01401-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T19:09:41Z","timestamp":1623438581000},"score":1,"resource":{"primary":{"URL":"https:\/\/systematicreviewsjournal.biomedcentral.com\/articles\/10.1186\/s13643-020-01401-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,12]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1401"],"URL":"https:\/\/doi.org\/10.1186\/s13643-020-01401-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-24099\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-24099\/v1","asserted-by":"object"}]},"ISSN":["2046-4053"],"issn-type":[{"value":"2046-4053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,12]]},"assertion":[{"value":"21 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study does not require institutional review board approval and participant consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"TAF reports personal fees from Mitsubishi-Tanabe, MSD, and Shionogi and a grant from Mitsubishi-Tanabe, outside the submitted work; TAF has a patent 2018-177688. GS was invited to participate in two methodological meetings about the use of real-world data, organized by Biogen and by Merck. All the other authors report no competing interests to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"140"}}